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Summary
Acromegaly is a chronic debilitating disorder re-
sulting from excessive secretion of growth hor-
mone (GH) and consequent increase in insulin-like
growth factor I (IGF-I), usually caused by a pitu-
itary somatotroph adenoma. Effective treatment
aims to ameliorate symptoms and signs of the dis-
ease and to lower mortality rate. In particular, high
morbidity and mortality are partly related to the
presence of insulin resistance due to the action of
GH on liver, muscle and adipose tissue. Insulin re-
sistance and/or reduced insulin sensitivity physio-
logically result in hypersecretion of insulin from
the pancreas. This compensatory state of hyperin-
sulinemia is felt to be a first and more important
marker for this condition. Adequate control of GH
excess by surgery or pharmacotherapy is associa-
ted with decreased insulin resistance, resulting in
reduced plasma insulin and glucose levels or im-
proved glucose tolerance. Despite divergent ef-
fects of both somatostatin and somatostatin ana-
logs on GH, insulin and glucagon secretion, and
glucose absorption, treatment with the somatosta-
tin analogs octreotide and lanreotide has only li-
mited effects on glucose metabolism. However,
glucose sensitivity has been formally examined
using a hyperinsulinemic euglycemic clamp only
in a minority of studies. Treatment with the GH-re-
ceptor antagonist pegvisomant improves insulin
sensitivity, thus decreasing circulating fasting in-
sulin and glucose levels. Assessment of insulin
secretion and glucose levels in acromegalic pa-
tients during administration of the above com-
pounds is thus mandatory.
KEY WORDS: acromegaly, insulin-resistance, glu-
cose homeostasis, pegvisomant, somatostatin analog,
octreotide, lanreotide.
Introduction
Acromegaly is a rare but severe endocrine disease re-
sulting from the increased release of growth hormone
(GH) and, consequentially, insulin-like growth factor I
(IGF-I) usually induced by a pituitary adenoma. This
slowly developing syndrome occurs with the same fre-
quency in men and women at any age and is charac-
terized by an increased mortality because of cardio-
vascular, respiratory, metabolic and oncologic compli-
cations (1, 2).
The therapeutic goal in acromegaly is to reduce mor-
bidity and mortality by removing tumor mass and
restoring GH and IGF-I values to normal range for age
and sex. High morbidity and mortality are reported as-
sociated to insulin resistance due to the action of GH
on liver, muscle and adipose tissue (3-5). 
Current available treatments for acromegaly include
neurosurgery, radiotherapy and medical therapy with
dopamine-agonists, somatostatin analogues and the
GH-receptor antagonist. In experienced hands, sur-
gery is able to induce the definitive cure from
acromegaly, according to the international criteria of
cure (6), in approximately 60% of patients (7). Howev-
er, in patients with large invasive tumors, representing
the vast majority of cases, surgery fails to achieve the
complete tumor removal and surgical effectiveness is
lower (8).
Radiotherapy, both conventional external-beam or
stereotactic radiosurgery with the use of gamma-knife,
is indicated for patients with recurrence or persistence
of disease activity after unsuccessful surgery and re-
sistant or intolerant to medical treatment. However,
limitations of radiotherapy include the very slow atten-
uation of GH and IGF-I levels, requiring more than 10
years to achieve the maximum hormonal control (9),
46 Reviews in Endocrinology and Metabolism 2013; 1 (1): 46-53
Review
Glucose homeostasis in acromegaly: 
pathogenesis and effects of treatment
©
 C
IC
 Ed
izi
on
i I
nt
er
az
ion
ali
and sometimes the secondary damage of near cere-
bral tissue or hypopituitarism (10, 11). 
Dopamine-agonists, such as bromocriptine and
cabergoline, are only partly effective (12). Particularly,
a recent meta-analysis (13) showed that cabergoline
is effective in inducing IGF-I normalization in 52% of
patients with mild hormonal excess, with a poor effec-
tiveness in those with aggressive disease. Somato-
statin agonists inhibit the secretion of growth hor-
mone, but GH and IGF-I normalization is achieved in
approximately 70% of patients (14). 
Acromegaly is also associated with alterations of lipid
metabolism, with the incidence of hypertriglyceridemia
being three times higher than normal population (15).
The reduction of GH to “safe” levels (< 2.5 μg/L) has
been reported to reduce mortality rate (16, 17); there-
fore, the aim of all treatments is to induce disease
control by suppressing GH/IGF-I hypersecretion to
normal levels and to prevent complications. 
This review aims at focusing on insulin resistance, a
known cause of metabolic complications commonly
associated to acromegaly, and particularly on its
pathogenesis and the role of the different therapeutic
approaches.
Epidemiology
It is known that growth hormone counteracts insulin
action on peripheral tissues causing insulin resistance
(18). Some studies have reported on a direct correla-
tion between circulating GH plasma levels and the de-
gree of glucose intolerance (19). Noteworthy, the de-
velopment of glucose intolerance has been related to
family history of diabetes and to the presence of hy-
pertension (20). Although limited data are available re-
garding the role of insulin action in acromegalic pa-
tients, the observation of hyperinsulinemia and/or im-
paired glucose tolerance in acromegaly suggests that
chronic hypersecretion of GH is associated with in-
sulin resistance (4, 21-27). The prevalence of overt di-
abetes mellitus in acromegaly largely differs among
studies, likely due to different patient series and eth-
nicity, higher age and longer disease duration, family
history of diabetes, concomitant presence of arterial
hypertension and hormonal levels. The prevalence of
impaired glucose tolerance ranged from 16 to 46%
among studies (28-30), whereas diabetes mellitus oc-
curs in about 10-25% of acromegalic patients and it
has been associated with increased mortality (2). Fur-
thermore, in acromegaly dyslipidemia is frequently re-
ported; particularly hypertriglyceridemia occurs in 19
to 44% of  patients and a positive correlation between
the serum insulin response to glucose load and in-
creased serum triglycerides concentrations has been
described (15). The increased cardiovascular morbid-
ity and mortality are, at least partly, consequent upon
the presence of insulin resistance and dyslipidemia. 
Moreover, in hyperinsulinemic patients blood pressure
is reportedly increased, and hyperinsulinemia-induced
sodium reabsorption may contribute to the increase in
blood pressure in acromegalic patients (31). In an
open transversal study, 130 consecutive treatment-
naive acromegalic patients were evaluated for glucose
metabolism and blood pressure (20), showing glucose
tolerance abnormalities and hypertension respectively
in 54% and 35.4% of cases. Particularly normotensive
patients with glucose tolerance alterations had an in-
creased prevalence of impaired diastolic (40%) and
systolic (32%) dysfunction (20). 
Pathogenesis
Insulin resistance and/or reduced insulin sensitivity
physiologically result in the pancreatic hypersecretion
of insulin. This compensatory state of hyperinsuline-
mia is felt to be a first and more important marker for
this condition. Insulin resistance is characterized by a
reduced response to a given amount of insulin (32)
and occurs in several diseases, including diabetes
mellitus (32, 33). It has been demonstrated that after
oral glucose tolerance test (OGTT) acromegalic pa-
tients with either normal or impaired glucose tolerance
have reduced peripheral tissue glucose uptake, likely
due to the insulin resistance in extra-hepatic tissue (3,
34, 35). The underlying pathophysiological mecha-
nisms are yet to be clarified, but a possible direct ac-
tion of GH excess at receptor level has been pro-
posed. GH hypersecretion appears to be associated
with downregulation of insulin receptors (IR), and de-
creased IR binding affinity has been found in liver and
skeletal muscle of transgenic mice for GH (36-38). In
acromegalic patients, changes in IR binding affinity, as
well as a decreased receptor expression and an in-
crease in the affinity of the unoccupied or empty re-
ceptor are reported (35). These changes have been
correlated to each other, as well as to the severity of
the increase in plasma insulin and GH levels. In exper-
imental conditions of prolonged exposure to chronic
GH excess, changes in IR auto-phosphorilation or ki-
nase activity have been found in rats (39-41).  On the
other hand, a post-binding alteration in insulin action
in hepatic and extra hepatic tissues has also been pro-
posed (4, 35). The decrease in maximally stimulated
glucose utilization and the lack of change in monocyte
and erythrocyte insulin binding suggest an impairment
in post-binding function (4). Several post-receptor
events are affected when cultured cells are exposed to
GH, suggesting that GH and insulin signalling may
converge at post-receptorial levels (42-44). GH has al-
so been shown to promote tyrosine phosphorylation of
IRS-1 and IRS-2 and their association with PI-3 kinase
in different GH responsive tissues (45-48). Another
mechanism by which GH exerts insulin resistance is
by the induction of some cellular proteins, such as
SOCS-1 and SOCS-6, that are able to inhibit IR sig-
nalling (49). A role of pancreatic b-cell dysfunction in
the pathogenesis of glucose intolerance in acromegaly
was also postulated: by comparing plasma pro-insulin,
immunoreactive insulin, C-peptide and blood glucose
concentrations during oral glucose load in normotoler-
ant acromegalic patients, it has been shown that
acromegalics had higher fasting insulin, pro-insulin
and C-peptide levels than controls, thus suggesting ei-
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ther that hyperproinsulinemia contributes to hyperin-
sulinemia, and that prolonged and excessive GH se-
cretion may affect pancreatic beta-cell function (35). In
acromegaly, glucose metabolism abnormalities progres-
sively occur: in the early stage patients show hyperin-
sulinism with normal or borderline glucose tolerance. In
the middle phase, a delayed insulin peak after glucose
load associated to normal or slightly impaired glucose
tolerance is reported. The third and last stage is charac-
terized by maximal pancreatic response in fasting condi-
tions with no further rise in insulin concentrations after
glucose injection (35).
The incidence of hypercholesterolemia is similar to
that of the general population, and different independ-
ent studies reported plasma cholesterol to be in-
creased (50), normal (51) or decreased (15) in pa-
tients with acromegaly. Furthermore, an increased
plasma concentration of lipoprotein (a), small dense
LDL and remnant-like lipoprotein particles (RLP) has
been reported (51-53). The incidence of type IV hyper-
triglyceridemia is three times higher than in normal
population (15). Lecithin/cholesterol acyl transferase
(LCAT), phospholipids transfer protein (PLTP) and
cholesteryl ester transfer protein (CETP) are proteins
involved in the intravascular metabolism of lipoprotein.
Plasma CETP, LCAT and PLTP activity has been
found decreased in acromegalic patients (54), possi-
bly contributing to increased cardiovascular risk in
these patients due to impaired reverse cholesterol
transport. 
In summary, in acromegaly it is not possible to identi-
fy a unique sequence of events leading to insulin re-
sistance. The primary defect is clearly the high levels
of GH; secondly, the plasma GH levels could directly
act in increasing basal insulin concentrations which in
turn could cause the decrease in receptor concentra-
tion and the alteration in the post-receptorial mecha-
nisms.
Effects of GH/IGF-I Suppression on insulin 
resistance
Biochemical control of acromegaly by normalization of
either GH or IGF-I levels predicts improvement in glu-
cose homeostasis (55). Both surgery and medical
treatment resulting in biochemical cure of acromegaly
have been shown to normalize fasting glucose and in-
sulin values (55).
Surgery
Glucose tolerance abnormalities dramatically im-
proves when normalization of circulating GH levels is
achieved by successful surgical or pharmacological
therapy. Impaired glucose tolerance (IGT) and dia-
betes mellitus are potentially cured if surgical tumor
resection is complete and plasma GH levels are nor-
malized, which occurs in approximately 70% of
acromegalic patients, whereas in 30% of cases im-
paired glucose tolerance could persist (56). Increased
insulin secretion may still occur after glucose adminis-
tration in some patients despite the normal glucose
metabolism and fasting insulin levels (57). 
Radiotherapy
A few studies have investigated the effects of radiation
therapy on glucose metabolism in acromegaly and
limited data are nowadays available. However, radio-
therapy treatment has reportedly positive effects on
glucose metabolism: the reduction in plasma GH lev-
els after radiotherapy correlate with the improvement
of glucose tolerance (58). 
Pharmacological therapy
Somatostatin analogs (SA) significantly improve
GH/IGF-I control, in particular in those patients not
completely cured by surgery (59). The effectiveness of
medical therapy either with SA or dopamine agonists
in improving glucose metabolism is controversial. Oc-
treotide is a SA which has been shown to be effective
in the treatment of acromegaly. It has been reported
that octreotide has beneficial effects on carbohydrate
metabolism. Ho et al. evaluated the effects of this SA
by performing a glucose tolerance test and an eug-
lycemic hyperinsulinemic clamp (60) showing the nor-
malization of glucose tolerance in 4 out of 5 patients
with impaired glucose tolerance without a significant
change in mean insulin concentrations. Thus the au-
thors conclude that octreotide improves both glucose
metabolism and insulin sensitivity by an increased
ability of insulin to suppress hepatic glucose produc-
tion; however the peripheral glucose uptake was not
affected by treatment. A positive experience has been
reported by Colao et al. (61). They reported the nor-
malization of blood glucose levels in 3 out of 7
acromegalic patients affected by diabetes and in 2 pa-
tients insulin has been replaced by oral hypoglycemic
agents, and in other 2 patients insulin dosage was re-
duced. The improvement in glucose metabolism was
associated with a significant reduction in serum GH
and IGF-I levels. However octreotide is not always ca-
pable to ameliorating carbohydrate metabolism; there
are some reports showing that it deteriorates glucose
tolerance in patients with acromegaly. The Internation-
al Multicenter Acromegaly Study Group (62) evaluated
the clinical and biochemical effects of long-term thera-
py with octreotide and reported a worsening of glu-
cose tolerance in 48% of 25 assessed patients. In 2
out of 25 acromegalic patients there was an ameliorat-
ing carbohydrate metabolism. Another study (63) in-
vestigated the effects of the SA on glucose tolerance
in 90 acromegalic patients. At baseline 11 patients
were diabetic, 24 had an impaired glucose tolerance
and 55 had normal glucose tolerance. During oc-
treotide therapy about 20% of patients who had nor-
mal carbohydrate metabolism have developed im-
paired glucose tolerance and 29% became frankly di-
abetic; 3 of 11 patients who were diabetic at baseline
became normal (18%) or developed impaired glucose
tolerance (9%). No relationship was observed be-
tween the dose of octreotide and the change in glu-
R. Baldelli et al.
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cose tolerance. Patients with elevated baseline insulin
levels were more likely to become diabetic; so this
study has showed a significant deterioration in glu-
cose metabolism both in acromegalic patients with
normal and impaired glucose tolerance. In the Italian
Multicenter Octreotide Study (64) it has been shown
that SA treatment is able to deteriorate the glucose tol-
erance in acromegaly: 25% of  patients with overt dia-
betes mellitus had an impairment of their metabolic
control after treatment with octreotide. The divergent
effects of octreotide on glucose tolerance may be ex-
plained by the multiple complex effects of this drug on
glucose metabolism (65, 66). Octreotide may induce
an increase in blood glucose concentration by inhibit-
ing insulin secretion from pancreatic beta cells. More-
over it has been reported that this SA increases IGF-
BP-1 concentration counteracting the insulin-like ef-
fect of IGF-I (67, 68). On the other hand octreotide
may induce a decrease in blood glucose levels by in-
hibiting GH and IGF-I hypersecretion. The reduction in
circulating GH levels can induce an inhibition of gluco-
neogenesis and an increase of insulin sensitivity with
an improved insulin action both at the receptor and
post-receptor level. Furthermore octreotide inhibits the
secretion of insulin, glucagon and other intestinal hor-
mones, reduces gastrointestinal movements and con-
sequently glucose absorption. These multiple effects
of octreotide at different steps involved in glucose me-
tabolism may explain the individual differences and
the unpredictable effect of this drug on glucose toler-
ance in acromegalic patients also if the genetic back-
ground of these patients must be taken in considera-
tion. The long-term follow up studies with long-acting
SA do not show any impairment of glucose tolerance
(69-71). Further studies are necessary to elucidate the
effects of these new formulations on glucose toler-
ance. We have published a paper where twenty-four
active acromegalic patients were studied in order to
determine the long-term effects of octreotide-LAR and
SR-lanreotide on insulin sensitivity and carbohydrate
metabolism (27). All patients underwent an oral glu-
cose tolerance test (OGTT) and 12 also had an eugly-
caemic hyperinsulinaemic clamp and were evaluated
at baseline and after 6 months of SA therapy. The re-
sults of these paper showed that acromegalic patients
had low M-values (insulin sensitivity index) in respect
to the control group at baseline, followed by a signifi-
cant improvement after 6 months of therapy. Moreover
serum glucose levels at 120 min during OGTT wors-
ened during SA therapy in patients with normal glu-
cose tolerance, but not in those with impaired glucose
tolerance or diabetes mellitus. This was associated
with a reduced and 30 min delayed insulin secretion
during OGTT. Also, HbA1c significantly deteriorated in
all subjects after treatment. It was concluded that in
acromegalic patients SA treatment reduces insulin re-
sistance, and also impairs insulin secretion suggesting
the use of oral secretagogue hypoglycaemic agents
and/or insulin therapy as treatment of choice in
acromegalic patients who develop frank hypergly-
caemia during somatostatin analogs therapy. More re-
cent evidences reported a similar prevalence of dete-
rioration and improvement of glucose tolerance 12
months after first-line SA treatment (72, 73), with un-
controlled acromegaly despite SA therapy and abnor-
mal glucose tolerance at baseline being associated
with glucose tolerance worsening. A recent study by
Giordano C et al. (74) compared the effects of first-line
SA or surgery on glucose metabolism in acromegaly.
Both treatments have been shown to improve insulin
sensitivity and visceral adiposity index (VAI), a new
marker of metabolic syndrome. Interestingly, success-
ful treatments able to normalize disease activity and to
ameliorate glucose tolerance have been shown to
shortly result in the improvement of quality of life in
acromegalic patients (74, 75).  
Dopamine agonists have controversial effects on glu-
cose tolerance, and no significant effect on glucose
metabolism has been reported (76).
New perspectives derive from pegvisomant, a pegylat-
ed GH analog that competes with wild-type GH for GH
receptor binding sites and prevents functional GH re-
ceptor dimerization, by the inhibition of the signal
transduction and IGF-I generation (77).
Pegvisomant-induced normalization of serum IGF-I,
an accepted marker of GH-dependent disease activity
(77), has been reported in approximately 80% of
acromegalic patients proven to be resistant to long-
term conventional SA therapy (78, 79). Control of
acromegaly induced by pegvisomant has been associ-
ated with an improvement of glycometabolic profile:
several studies (80-85) have demonstrated that pegvi-
somant induces a significant decrease in fasting glu-
cose until normal levels also in patients with diag-
nosed diabetes mellitus and impaired glucose toler-
ance, and improves insulin resistance by the reduction
of HOMA-index and the increase of pancreatic β-cell
secretory function (HOMA-β).
Co-administration of pegvisomant and SA showed dis-
cordant effects on glucose homeostasis in different
series of acromegalic patients (86-88). However, it is
a matter of fact that a good control of hyperglycemia
can be successfully achieved in the majority of
acromegalic patients with overt diabetes or impaired
glucose tolerance, independently on the administered
treatment to control GH excess. 
Only a study (89) compared the effects of SA and
pegvisomant, either as monotherapy or combined
treatment, on glucose profile in acromegaly. Fasting
plasma glucose levels significantly vary during the
study, being highest during SA treatment and lowest
levels during pegvisomant therapy: 5.9 ± 0.3 mmol/L
while on somatostatin analogs, 5.4 ± 0.4 mmol/L in ac-
tive patients after somatostatin analogs discontinua-
tion, 5.0 ± 0.2 mmol/L during pegvisomant 10 mg , 4.7
± 0.2 on pegvisomant 15 mg, and 5.3 ± 0.3 while on
combined treatment (p= 0.02). 
When both surgical or medical treatment of acromegaly
are ineffective in ameliorate the glucose intolerance
and insulin resistance it should be necessary to start a
specific treatment. 
In conclusion, glucose homeostasis disorders occur in
at least one third of acromegalic patients. GH and
IGF-I excess lead to insulin resistance by increasing
Glucose homeostasis in acromegaly: pathogenesis and effects of treatment
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basal insulin concentrations and/or affecting receptor
expression and post-receptorial mechanisms. Disease
control is associated with a significant improvement of
insulin resistance and glycometabolic profile, although
medical therapy with SA is reported to induce either
deterioration or improvement of glucose tolerance,
with uncontrolled acromegaly despite SA therapy and
abnormal glucose tolerance at baseline being associ-
ated with glucose tolerance worsening. Pegvisomant
improves insulin resistance and induces a significant
decrease in fasting glucose up to normalization in
acromegalic patients with diagnosed diabetes mellitus
and impaired glucose tolerance. Further studies are
still needed to confirm and extend these data. 
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